Navigation Links
LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders

LOS ANGELES (May 30, 2012) Patricia Dickson, M.D., principal investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is co-principal investigator of a project that was just awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The goal of the project is to develop a stem cell based therapy for the treatment of mucopolysaccharidosis I (MPS I), a fatal pediatric lysosomal storage disease that causes neurodegeneration as well as defects in other major organ systems. Dr. Dickson is working with lead investigator Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children's Research Institute and managing director of the facility's National Human Neural Stem Cell Resource.

For nearly a decade, Dr. Dickson's research at LA BioMed has focused on enzyme replacement therapy for mucopolysaccharidosis, a group of metabolic disorders caused by the absence or malfunctioning of enzymes needed to break down molecules - called glycosaminoglycans - which help build bone, cartilage, connective tissue and other essential parts of the body. As part of this study, she and her colleagues will begin with proof-of-principle experiments for MPS I.

"Dr. Dickson has been at the forefront of mucopolysaccharidosis research for many years, working tirelessly to help develop therapies for MPS I," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "We congratulate her on her continued success, and for her role in this project which could be an important breakthrough for children suffering from neurodegenerative disorders."

"The unique aspect of this research is that it uses a single donor for the transplantation of stem cells into the body and the brain, which allows the best treatment for both physical and neurological disease and avoids rejection of neural stem cell grafts by the host immune system," said Dr. Dickson. "Pediatric neurodegenerative diseases are generally neglected in stem cell research, but stand the greatest chance of success. The high probability of success, along with the need to alleviate suffering in children, is why we believe the first applications of stem cell therapies should be for these kids."

Dr. Schwartz, Dr. Dickson and project collaborators are working to address two critical issues in the development of a therapeutic candidate based on stem cells: that early intervention is not only required but is indeed possible in this patient population, and that the concept of immune tolerance is also required, where the immune system is trained to attack only real threats in the body but not the body's own cells or tissues.

To date, there is still a significant unmet medical need to better impact and prevent the neurodegenerative processes in this disease. If successful in MPS I, this technique can be expanded to help treat other neurodegenerative disorders due to lysosomal storage.


Contact: Diana Soltesz
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)

Related medicine news :

1. Sodexo Names Patricia Bellinger to North America Advisory Board
2. What Causes A Person To Be Mentally Ill? Author Who Has Spent Decades Researching Topic Says He Has the Answer
3. Global Basecamps Launches New Website: Researching and Booking Sustainable Travel Has Never Been Easier
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Charging less for more effective treatments could reduce health care costs while improving health
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
8. Two Sepsis Treatments Look Equally Effective
9. Heart Stem Cells Move Closer to Human Treatments
10. New Ankle Arthritis Treatments Help Boomers Stay Active
11. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction
Post Your Comments:
(Date:10/12/2015)... , ... October 12, 2015 , ... Advera Health ... no charge to qualified Managed Care Organizations (MCOs) in order to provide health plans, ... into their decision making process. In addition, the DSM is also being offered to ...
(Date:10/12/2015)... ... October 12, 2015 , ... To ... announced its charitable donation to the National Breast Cancer Foundation. The National Breast ... by breast cancer through early detection, education, and support services. , The annual ...
(Date:10/12/2015)... ... ... Clara dentist , Dr. Alan Frame, shares his insight on today’s dental hygiene and the ... “I want each one of my patients to be at their optimum level of health, ... implants dentist , Dr. Frame. He mentions, "As the white paper mentions, oral health care ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) ... the research community. , The project, entitled “Training Patients with Asthma to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... secured a new corporate headquarters, located at 485 Madison Avenue, New York, NY ... and increased emphasis on cloud-based technology. , “Care to Care is a dynamic ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... Cell Therapy Catapult to advance development of large ... cell immunotherapy. Under the agreement, the Cell Therapy ... AST-VAC2 to support advanced clinical trials and eventual ... --> The Cell Therapy Catapult is ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
Breaking Medicine Technology: